BioEngine is a leading cell culture media company founded in 2014 in Shanghai, China. BioEngine specializes in high-density, serum-free suspension culture of animal cells and provides biopharmaceutical companies with premium one-stop services from the development and optimization of the cell culture process, and medium formulation design to media processing and manufacturing.
With more than 30 years of experience and expertise in animal cell culture process and bioreactor engineering, the founding team of BioEngine has successfully developed nearly 100 types of catalog serum-free media. These media have been extensively utilized in over 100 clinical projects in the biopharmaceutical industry, including antibodies, vaccines, and stem cell/cell therapy. BioEngine has also provided cell culture technology services for numerous projects, earning recognition for several “first in China” and “world’s first” achievements.
BioEngine’s Phase II production base achieved full-scale production in 2021. The production base is a state-of-the-art facility built in compliance with the ISO13485:2016 quality management system and GMP requirements. It implements the LSS Lean 6 Sigma system for production management, enabling the construction of large-scale low-temperature Cone Mix/ Pin Milling processes with capacities ranging from thousands to hundreds of thousands of liters. The facility has a maximum batch size of 100,000 liters and an annual production capacity of 55 million liters of powder culture media and 250,000 liters of liquid culture media.
BioEngine is committed to being the most reliable cell culture partner in the world.